Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Recruiting · NCT05950139 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-28 | NCT05950139 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Oncovir, Inc. | 6 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University | Baltimore | United States | 150 |